Adjuvant Entecavir or Tenofovir for Hepatitis B Virus Related Hepatocellular Carcinoma After Curative Hepatic Resection
Who is this study for? Adults with Hepatocellular Carcinoma
Status: Completed
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
This study aims to compare the effect of antiviral therapy with entecavir or tenofovir for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy. Included patients will randomly divide into two groups.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: t
View:
• Underwent hepatic resection.
• Diagnosis of HCC was confirmed by postoperative histopathology.
• Positive of HBsAg, HBeAg, or HBV DNA.
• Child-Pugh A or B liver function.
Locations
Other Locations
China
Department of Hepatobilliary Surgery, Affiliated Tumor of Guangxi University
Nanning
Time Frame
Start Date: 2021-02-02
Completion Date: 2023-12-30
Participants
Target number of participants: 240
Treatments
Experimental: Entecavir
Patients will be received entecavir (10 mg/d) after 3 days of liver resection.
Active_comparator: Tenofovir
Patients will be received tenofovir (1#/d) after 3 days of liver resection.
Related Therapeutic Areas
Sponsors
Leads: Guangxi Medical University